Effects of statin therapy on vascular dysfunction

Coronary Artery Disease

Volumn 15, Issue 5, 2004, Pages 227-233

  Aikawa, Masanori ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Atherosclerosis; Endothelial cells; HMG CoA reductase inhibitor; Inflammation; Macrophages; Oxidative stress; Plaque stabilization; Statin; Vascular biology

Indexed keywords

ATORVASTATIN; CD40 LIGAND; CERIVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR INFLAMMATION; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM LESION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LOW FAT DIET; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOGENESIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 4043066515     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000132583.04711.47     Document Type: Review

References (78)

1. Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363-373. Using careful pathologic approaches, this pioneering work proposed the concept of plaque disruption that contributes to the onset of acute coronary events. Dr. Davies' concept also challenged conventional thought that occlusive plaques, detectable by angiography as luminal stenoses, trigger most myocardial infarctions.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844-2850. This review proposed the molecular mechanisms that form vulnerable atherosclerotic plaques prone to disruption, leading to acute thrombotic complications. In particular, the article recognized interstitial collagen as a key determinant of plaque stability, and hypothesized that imbalance of collagen synthesis by vascular smooth muscle cells and breakdown by macrophage-derived enzymes (i.e., MMPs) destabilize the plaque.
3. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-2503.
4. Sukhova G, Schoenbeck U, Rabkin E, Schoen F, Poole A, Billinghurst R, et al. Evidence of increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99:2503-2509.
5. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104:1899-1904.
6. Libby P, Mach F, Schoenbeck U, Bourcier T, Aikawa M. Regulation of the thrombotic potential of atheroma. Thromb Haemost 1999; 82:736-741.
7. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr., et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute, The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81:1721-1733.
8. Libby P, Aikawa M, Schonbeck U. Cholesterol and atherosclerosis. Biochim Biophys Acta 2000; 1529:299-309.
9. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924. By establishing the concept that oxidatively modified LDL induces pro-inflammatory and pro-atherogenic phenotypes of vascular cells, Steinberg et al. linked the clinical evidence for the critical role of hypercholesterolemia in coronary events to vascular biology.
10. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Circulation 2003; 108:1912-1916, 2034-2040. This series of review articles extensively discusses current understanding of the role of oxidative stress in vascular disease.
11. Kume N, Cybulsky MI, Gimbrone MA, Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90:1138-1144. This is one of earliest studies that demonstrated that oxidative lipids elicit endothelial cell activation gauged by induction of cell adhesion molecules and lead to leukocyte invasion.
12. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low-density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995; 95:1262-1270.
13. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87:5134-5138. Cushing's pioneering work showing that oxidative stress induces inflammation in the arterial wall via vascular cell activation.
14. Collins T, Cybulsky MI. NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107:255-264.
15. Sakai M, Kobori S, Miyazaki A, Horiuchi S. Macrophage proliferation in atherosclerosis. Curr Opin Lipidol 2000; 11:503-509.
16. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994; 89:2176-2182. This study demonstrated that NO's atheroprotective role can suppress interaction between leukocytes and endothelial cells.
17. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J Clin Invest 1995; 96:60-68.
18. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996; 93:9114-9119.
19. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96:934-940.
20. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270:319-324. This study reported another important role of oxidative stress in atherogenesis. Their in vitro experiments demonstrated that oxidized LDL reduces expression of endothelial NO synthase that produces atheroprotective NO.
21. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998; 97:2494-2498.
22. Aikawa M, Sugiyama S, Hill C, Voglic S, Rabkin E, Fukumoto Y, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002; 106:1390-1396.
23. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89:6998-7002.
24. Gatto AM, Farmer JA. Lipid-Lowering Trials. In: Braunwald E, Zipes DP, Libby P, (Eds.), Heart Disease: A Text Book of Cardiovascular Medicine. Philadelphia:W.B. Saunders; 2001:126-146.
25. Aikawa M, Libby P. The vulnerable atherosclerotic plague: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13:125-138. A review of the current understanding of mechanisms of plaque stabilization.
26. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87:1781-1791. One of early articles that established the concept of plaque stabilization.
27. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97:2433-2444. Using a rabbit model, this pre-clinical study demonstrated that dietary lipid lowering reduces the expression or activity of various MMPs including MMP-1/collagenase-1 and increases collagen content in atheroma. These results suggest a critical role of collagenase in collagen metabolism and a potential mechanism of plaque stabilization.
28. Aikawa M, Rabkin E, Voglic SJ, Shing H, Nagai R, Schoen FJ, et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 1998; 83:1015-1026.
29. Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999; 100:1215-1222.
30. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31:684-691.
31. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103:276-283. Aikawa et al., reported that statin treatment in vitro with clinically-achievable concentrations reduced macrophage growth and proliferation, suggesting potential lipid-independent effects of statins. This study also demonstrated that lipid lowering by statin treatment reduces expression of MMPs, tissue factor, and their inducer CD40 ligand in rabbit atheroma.
32. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103:993-999.
33. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110:285-288. This review focuses on the molecular mechanisms of lipid-independent effects of statins.
34. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41:37S-42S.
35. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109:647-655. Accumulating in vitro evidence suggests that CRP not only predicts cardiovascular risks but also accelerates inflammation. This in vivo study, using transgenic mice that over-express human CRP, reported that this protein induces atheroma progression.
36. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108:512-515. Recent in vitro studies demonstrate that CRP may induce thrombus formation via increasing pro-thrombotic or anti-fibrinolytic molecules. This in vivo study on CRP transgenic mice demonstrated that CRP might induce thrombus formation acutely, suggesting a more direct role of this protein in thrombotic complications of atherosclerosis in patients.
37. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17:265-272.
38. Laufs U, La Fata V, Plutzky J, Liao JK. Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-1135.
39. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83:490-500.
40. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-1402.
41. Mulhaupt F, Matter CM, Kwak BR, Pelli G, Veillard NR, Burger F, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59:755-766.
42. Mach F. Statins as novel immune-modulators: from cell to potential clinical benefit. Thromb Haemost 2003; 90:607-610.
43. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct anti-inflammatory mechanisms contribirte to allenuation of experimental allograft arteriosclerosis by Statins. Circulation 2003; 108:2113-2120.
44. Sakai M, Kobori S, Matsumura T, Biwa T, Sato Y, Takemura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997; 133:51-59.
45. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18:1671-1678.
46. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003; 23:512-517.
47. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89:2519-2524. This and other clinical studies (references 48, 49, 50) established that lipid lowering improves endothelial function in hypercholesterolemic patients.
48. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
49. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
50. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95:76-82.
51. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21:122-128.
52. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88: 1306-1307. This clinical study reported that a maximum dose of statin treatment surprisingly improves endothelial function within 24 hours in healthy, normocholesterolemic subjects, suggesting lipid-independent effects of statin treatment. Other studies (references 53, 54) also demonstrated similar results.
53. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within three days. Circulation 2001; 104:376-379.
54. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93:e98-e103.
55. Leonhardt W, Kurktschiev T, Meissner D, Lattke P, Abletshauser C, Weidinger G, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol 1997; 63:65-69.
56. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003; 90:317-321.
57. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammalory pathways. Circulation 2003; 108:426-431.
58. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423. Law's comprehensive review of statin clinical trials focuses on similarities and differences among drugs and doses. In particular, the article demonstrates strong relationships between cholesterol reduction and risk prevention in all trials.
59. Lesaffre E, Kocmanova D, Lemos PA, Disco CM, Serruys PW. A retrospective analysis of the effect of non-compliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003; 25:2431-2447.
60. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-235. A sub-study of the CARE trial demonstrated that magnitudes of reduction in individual high-sensitivity CRP levels by 5-years of pravastatin treatment were not associated with those of LDL reduction, suggesting a lipid-independent, anti-inflammatory effects of statin treatment.
61. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103:1191-1193.
62. Kinlay S, Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002; 89:1205-1207.
63. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108:1560-1606.
64. Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001; 11:328-343.
65. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055-2060.
66. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166:129-135.
67. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87:25C-32C.
68. Bocan TM, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000; 20:70-79.
69. Perrey S, Legendre C, Matsuura A, Guffroy C, Binet J, Ohbayashi S, et al. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. Atherosclerosis 2001; 155:359-370.
70. Ziouzenkova O, Perrey S, Marx N, Bacqueville D, Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep 2002; 4:59-64.
71. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000; 58:1420-1430.
72. Dechend R, Fiebler A, Lindschau C, Bischoff H, Muller D, Park JK, et al. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 2001; 14:55S-61S.
73. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107:1423-1432.
74. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, et al. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002; 290:131-139.
75. Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 2003; 3:186-191.
76. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin and fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003; 92:794-797.
77. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107:2409-2415.
78. Kastelein J. What future for combination therapies? Int J Clin Pract Suppl 2003; 134:45-50.